IL233712A0 - Sulfonamide derivatives used as mogat–2 inhibitors - Google Patents
Sulfonamide derivatives used as mogat–2 inhibitorsInfo
- Publication number
- IL233712A0 IL233712A0 IL233712A IL23371214A IL233712A0 IL 233712 A0 IL233712 A0 IL 233712A0 IL 233712 A IL233712 A IL 233712A IL 23371214 A IL23371214 A IL 23371214A IL 233712 A0 IL233712 A0 IL 233712A0
- Authority
- IL
- Israel
- Prior art keywords
- mogat
- inhibitors
- derivatives useful
- sulfonamide derivatives
- benzyl sulfonamide
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title 1
- ABOYDMHGKWRPFD-UHFFFAOYSA-N phenylmethanesulfonamide Chemical class NS(=O)(=O)CC1=CC=CC=C1 ABOYDMHGKWRPFD-UHFFFAOYSA-N 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
- C07D213/64—One oxygen atom attached in position 2 or 6
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
- C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
- C07C311/03—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the sulfonamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C311/05—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the sulfonamide groups bound to hydrogen atoms or to acyclic carbon atoms to acyclic carbon atoms of hydrocarbon radicals substituted by nitrogen atoms, not being part of nitro or nitroso groups
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
- C07D213/65—One oxygen atom attached in position 3 or 5
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Pyridine Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261592717P | 2012-01-31 | 2012-01-31 | |
| EP12382432 | 2012-11-06 | ||
| PCT/US2013/022870 WO2013116075A1 (en) | 2012-01-31 | 2013-01-24 | Benzyl sulfonamide derivatives useful as mogat - 2 inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL233712A0 true IL233712A0 (en) | 2014-09-30 |
Family
ID=47148691
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL233712A IL233712A0 (en) | 2012-01-31 | 2014-07-17 | Sulfonamide derivatives used as mogat–2 inhibitors |
Country Status (27)
| Country | Link |
|---|---|
| US (1) | US8575352B2 (OSRAM) |
| EP (1) | EP2809651B1 (OSRAM) |
| JP (1) | JP2015511232A (OSRAM) |
| KR (1) | KR20140106750A (OSRAM) |
| CN (1) | CN104066719B (OSRAM) |
| AP (1) | AP2014007794A0 (OSRAM) |
| AR (1) | AR089771A1 (OSRAM) |
| AU (1) | AU2013215468A1 (OSRAM) |
| BR (1) | BR112014018636A8 (OSRAM) |
| CA (1) | CA2859995A1 (OSRAM) |
| CL (1) | CL2014001861A1 (OSRAM) |
| CO (1) | CO7010839A2 (OSRAM) |
| CR (1) | CR20140322A (OSRAM) |
| DO (1) | DOP2014000178A (OSRAM) |
| EA (1) | EA201491276A1 (OSRAM) |
| ES (1) | ES2590929T3 (OSRAM) |
| GT (1) | GT201400167A (OSRAM) |
| HK (1) | HK1199025A1 (OSRAM) |
| IL (1) | IL233712A0 (OSRAM) |
| MA (1) | MA35886B1 (OSRAM) |
| MX (1) | MX2014008599A (OSRAM) |
| PE (1) | PE20141679A1 (OSRAM) |
| PH (1) | PH12014501711A1 (OSRAM) |
| SG (1) | SG11201404106QA (OSRAM) |
| TW (1) | TW201343629A (OSRAM) |
| WO (1) | WO2013116075A1 (OSRAM) |
| ZA (1) | ZA201404836B (OSRAM) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9073856B2 (en) | 2012-01-23 | 2015-07-07 | Eli Lilly And Company | Phenyl methanesulfonamide derivatives useful as MGAT-2 inhibitors |
| SG11201404508XA (en) | 2012-01-31 | 2014-10-30 | Lilly Co Eli | Novel morpholinyl derivatives useful as mogat-2 inhibitors |
| WO2014074365A1 (en) | 2012-11-06 | 2014-05-15 | Eli Lilly And Company | Novel benzyl sulfonamide compounds useful as mogat-2 inhibitors |
| WO2016202341A1 (en) | 2015-06-15 | 2016-12-22 | Nmd Pharma Aps | Compounds for use in treating neuromuscular disorders |
| TWI782056B (zh) | 2017-07-14 | 2022-11-01 | 日商鹽野義製藥股份有限公司 | 具有ｍｇａｔ２抑制活性的縮合環衍生物 |
| US11730714B2 (en) | 2017-12-14 | 2023-08-22 | Nmd Pharma A/S | Compounds for the treatment of neuromuscular disorders |
| US12440477B2 (en) | 2017-12-14 | 2025-10-14 | Nmd Pharma A/S | Compounds for the treatment of neuromuscular disorders |
| US11147788B2 (en) | 2017-12-14 | 2021-10-19 | Nmd Pharma A/S | Compounds for the treatment of neuromuscular disorders |
| US11591284B2 (en) | 2017-12-14 | 2023-02-28 | Nmd Pharma A/S | Compounds for the treatment of neuromuscular disorders |
| US10385028B2 (en) | 2017-12-14 | 2019-08-20 | Nmd Pharma A/S | Compounds for the treatment of neuromuscular disorders |
| KR20210114001A (ko) | 2019-01-11 | 2021-09-17 | 시오노기 앤드 컴파니, 리미티드 | Mgat2 저해 활성을 갖는 다이하이드로피라졸로피라지논 유도체 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1659113A1 (en) * | 2004-11-08 | 2006-05-24 | Evotec AG | Inhibitors of 11beta-hydroxy steroid dehydrogenase type 1 (11beta-HSD1) |
| EP1655283A1 (en) * | 2004-11-08 | 2006-05-10 | Evotec OAI AG | 11beta-HSD1 Inhibitors |
| CN101087771A (zh) * | 2004-11-10 | 2007-12-12 | 辉瑞大药厂 | 经取代n－磺酰基氨基苄基－2－苯氧基乙酰胺化合物 |
| ATE404546T1 (de) * | 2004-11-10 | 2008-08-15 | Pfizer | Substituierte n-sulfonylaminobenzyl-2- phenoxyacetamidverbindungen |
| CA2662766C (en) * | 2006-09-08 | 2011-08-09 | Pfizer Products Inc. | Diaryl ether derivatives and uses thereof |
| JPWO2008038768A1 (ja) * | 2006-09-28 | 2010-01-28 | 大日本住友製薬株式会社 | 二環性ピリミジン構造を有する化合物及びそれを含有する医薬組成物 |
| CN101583593A (zh) * | 2006-11-13 | 2009-11-18 | 辉瑞产品公司 | 二芳基、二吡啶基和芳基-吡啶基衍生物及其用途 |
| US8642660B2 (en) * | 2007-12-21 | 2014-02-04 | The University Of Rochester | Method for altering the lifespan of eukaryotic organisms |
| AU2010216633A1 (en) * | 2009-02-23 | 2011-09-08 | Msd K.K. | Pyrimidin-4(3H)-one derivatives |
| US9073856B2 (en) | 2012-01-23 | 2015-07-07 | Eli Lilly And Company | Phenyl methanesulfonamide derivatives useful as MGAT-2 inhibitors |
| SG11201404508XA (en) | 2012-01-31 | 2014-10-30 | Lilly Co Eli | Novel morpholinyl derivatives useful as mogat-2 inhibitors |
-
2013
- 2013-01-21 TW TW102102260A patent/TW201343629A/zh unknown
- 2013-01-21 AR ARP130100180A patent/AR089771A1/es unknown
- 2013-01-24 BR BR112014018636A patent/BR112014018636A8/pt not_active IP Right Cessation
- 2013-01-24 JP JP2014555589A patent/JP2015511232A/ja not_active Ceased
- 2013-01-24 AU AU2013215468A patent/AU2013215468A1/en not_active Abandoned
- 2013-01-24 EA EA201491276A patent/EA201491276A1/ru unknown
- 2013-01-24 HK HK14112466.4A patent/HK1199025A1/xx unknown
- 2013-01-24 AP AP2014007794A patent/AP2014007794A0/xx unknown
- 2013-01-24 PE PE2014001197A patent/PE20141679A1/es not_active Application Discontinuation
- 2013-01-24 SG SG11201404106QA patent/SG11201404106QA/en unknown
- 2013-01-24 WO PCT/US2013/022870 patent/WO2013116075A1/en not_active Ceased
- 2013-01-24 KR KR1020147021127A patent/KR20140106750A/ko not_active Ceased
- 2013-01-24 MX MX2014008599A patent/MX2014008599A/es unknown
- 2013-01-24 CA CA2859995A patent/CA2859995A1/en not_active Abandoned
- 2013-01-24 CN CN201380007085.XA patent/CN104066719B/zh active Active
- 2013-01-24 ES ES13703234.8T patent/ES2590929T3/es active Active
- 2013-01-24 EP EP13703234.8A patent/EP2809651B1/en active Active
- 2013-01-24 US US13/748,627 patent/US8575352B2/en not_active Expired - Fee Related
-
2014
- 2014-06-30 ZA ZA2014/04836A patent/ZA201404836B/en unknown
- 2014-07-04 CR CR20140322A patent/CR20140322A/es unknown
- 2014-07-15 CL CL2014001861A patent/CL2014001861A1/es unknown
- 2014-07-17 IL IL233712A patent/IL233712A0/en unknown
- 2014-07-24 CO CO14161422A patent/CO7010839A2/es unknown
- 2014-07-24 MA MA37244A patent/MA35886B1/fr unknown
- 2014-07-29 GT GT201400167A patent/GT201400167A/es unknown
- 2014-07-30 PH PH12014501711A patent/PH12014501711A1/en unknown
- 2014-07-30 DO DO2014000178A patent/DOP2014000178A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US8575352B2 (en) | 2013-11-05 |
| DOP2014000178A (es) | 2014-08-31 |
| ES2590929T3 (es) | 2016-11-24 |
| MX2014008599A (es) | 2014-08-22 |
| EP2809651B1 (en) | 2016-06-29 |
| HK1199025A1 (en) | 2015-06-19 |
| CO7010839A2 (es) | 2014-07-31 |
| US20130197039A1 (en) | 2013-08-01 |
| BR112014018636A8 (pt) | 2017-07-11 |
| GT201400167A (es) | 2015-05-28 |
| CR20140322A (es) | 2014-08-25 |
| BR112014018636A2 (OSRAM) | 2017-06-20 |
| AR089771A1 (es) | 2014-09-17 |
| MA35886B1 (fr) | 2014-12-01 |
| TW201343629A (zh) | 2013-11-01 |
| EA201491276A1 (ru) | 2014-10-30 |
| ZA201404836B (en) | 2017-08-30 |
| PE20141679A1 (es) | 2014-11-08 |
| AU2013215468A1 (en) | 2014-07-10 |
| CN104066719A (zh) | 2014-09-24 |
| WO2013116075A1 (en) | 2013-08-08 |
| SG11201404106QA (en) | 2014-08-28 |
| CA2859995A1 (en) | 2013-08-08 |
| JP2015511232A (ja) | 2015-04-16 |
| CL2014001861A1 (es) | 2014-11-07 |
| KR20140106750A (ko) | 2014-09-03 |
| AP2014007794A0 (en) | 2014-07-31 |
| PH12014501711A1 (en) | 2014-10-13 |
| EP2809651A1 (en) | 2014-12-10 |
| CN104066719B (zh) | 2016-08-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201501009B (en) | Imidazotriazinecarbonitriles useful as kinase inhibitors | |
| LT2841428T (lt) | Dnr-pk inhibitoriai | |
| ZA201305826B (en) | Substituted amminobutyric derivatives as neprilysin inhibitors | |
| ZA201409422B (en) | Benzimidazole-proline derivatives | |
| ZA201408876B (en) | Pyrrolotriazinone derivatives | |
| IL233712A0 (en) | Sulfonamide derivatives used as mogat–2 inhibitors | |
| EP2870140B8 (en) | Tetrahydroquinazolinone derivatives as parp inhibitors | |
| IL247637B (en) | History of heteroaryl piperidine | |
| LT2838883T (lt) | Nauji feniltetrahidroizochinolino dariniai | |
| ZA201502175B (en) | Oxazolidin-2-one-pyrimidine derivatives | |
| IL235919A0 (en) | inhibitors of fbxo3 | |
| ZA201405227B (en) | Novel morpholinyl derivatives useful as mogat-2 inhibitors | |
| SG11201404325VA (en) | Pyrimidooxazocine derivatives as mtor - inhibitors | |
| ZA201502878B (en) | Novel benzyl sulfonamide compounds useful as mogat-2 inhibitors |